Zhi-Xian Zhong

Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy

Immune checkpoint blockade (ICB) therapy has achieved clinical progress in various malignancies, yet primary and acquired resistance limits its efficacy in solid tumors. Myeloid cells in the tumor microenvironment (TME), including tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and myeloid-der...